

Dab/Tram (dabrafenib and trametinib) ROAR, NCI-MATCH (subprotocol H)

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Dab/Tram (dabrafenib and trametinib) ROAR, NCI-MATCH (subprotocol H)

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Tumour agnostic  
 Therapeutic Indication: Adult and paediatric patients ≥1 year of age with unresectable or metastatic solid tumours with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options  
 Experimental Arm: Dab/Tram (dabrafenib and trametinib)  
 Control Arm: Single arm



